Concepts (63)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| T-Lymphocytes | 3 | 2024 | 1691 | 1.350 |
Why?
|
| Glypicans | 1 | 2024 | 39 | 0.930 |
Why?
|
| Interleukin-15 | 1 | 2024 | 91 | 0.900 |
Why?
|
| Immunotherapy, Adoptive | 4 | 2025 | 821 | 0.860 |
Why?
|
| Hematologic Neoplasms | 2 | 2025 | 286 | 0.830 |
Why?
|
| Neoplasms | 4 | 2025 | 2758 | 0.790 |
Why?
|
| Sarcoma, Ewing | 1 | 2019 | 116 | 0.590 |
Why?
|
| Cystic Fibrosis | 1 | 2019 | 257 | 0.530 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2019 | 448 | 0.490 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2024 | 1200 | 0.490 |
Why?
|
| Genetic Therapy | 1 | 2019 | 678 | 0.470 |
Why?
|
| Patient Safety | 1 | 2019 | 394 | 0.470 |
Why?
|
| Catheter-Related Infections | 2 | 2024 | 131 | 0.380 |
Why?
|
| Graft vs Host Disease | 2 | 2023 | 543 | 0.330 |
Why?
|
| beta-Thalassemia | 1 | 2023 | 28 | 0.220 |
Why?
|
| Antibodies, Bispecific | 1 | 2023 | 34 | 0.210 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2023 | 47 | 0.210 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 123 | 0.200 |
Why?
|
| Burkitt Lymphoma | 1 | 2023 | 146 | 0.200 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2022 | 70 | 0.190 |
Why?
|
| Ambulatory Care Facilities | 1 | 2023 | 229 | 0.190 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 324 | 0.180 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2019 | 57 | 0.160 |
Why?
|
| Cross Infection | 1 | 2022 | 330 | 0.160 |
Why?
|
| Cytokines | 1 | 2024 | 1284 | 0.160 |
Why?
|
| Quality Improvement | 1 | 2024 | 626 | 0.160 |
Why?
|
| Humans | 12 | 2025 | 123072 | 0.150 |
Why?
|
| Sepsis | 1 | 2022 | 477 | 0.150 |
Why?
|
| Forecasting | 1 | 2019 | 354 | 0.140 |
Why?
|
| Cell Proliferation | 1 | 2024 | 2307 | 0.140 |
Why?
|
| Child | 8 | 2025 | 24226 | 0.140 |
Why?
|
| Follow-Up Studies | 2 | 2025 | 5048 | 0.140 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 805 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2019 | 477 | 0.120 |
Why?
|
| Cohort Studies | 1 | 2024 | 4703 | 0.120 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 664 | 0.120 |
Why?
|
| Retrospective Studies | 4 | 2025 | 16039 | 0.110 |
Why?
|
| Adult | 2 | 2024 | 29010 | 0.110 |
Why?
|
| Genomics | 1 | 2019 | 1475 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2019 | 3317 | 0.080 |
Why?
|
| Male | 3 | 2025 | 60081 | 0.080 |
Why?
|
| Female | 3 | 2025 | 65528 | 0.070 |
Why?
|
| Aged | 1 | 2024 | 19094 | 0.070 |
Why?
|
| Middle Aged | 1 | 2024 | 25992 | 0.060 |
Why?
|
| Oral Health | 1 | 2024 | 17 | 0.060 |
Why?
|
| Infant | 3 | 2025 | 12355 | 0.060 |
Why?
|
| Child, Preschool | 3 | 2025 | 13881 | 0.060 |
Why?
|
| Alemtuzumab | 1 | 2023 | 88 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2019 | 12123 | 0.050 |
Why?
|
| Busulfan | 1 | 2023 | 44 | 0.050 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2023 | 141 | 0.050 |
Why?
|
| Chlorhexidine | 1 | 2022 | 46 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2023 | 659 | 0.050 |
Why?
|
| Transplantation Conditioning | 1 | 2023 | 323 | 0.050 |
Why?
|
| Personal Satisfaction | 1 | 2022 | 102 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 422 | 0.050 |
Why?
|
| Recurrence | 1 | 2023 | 1419 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 2022 | 578 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2022 | 477 | 0.040 |
Why?
|
| Adolescent | 2 | 2025 | 19096 | 0.030 |
Why?
|
| Prognosis | 1 | 2025 | 4513 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2025 | 1862 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2023 | 6027 | 0.030 |
Why?
|